代谢手术术前内科管理进展
单颖仪, 于浩泳

Advances in preoperative medical management of metabolic surgery
SHAN Yingyi, YU Haoyong
表1 口服降糖药物和非胰岛素注射剂术前治疗建议
Tab 1 Recommendations for preoperative treatment with oral hypoglycemic agents and non-insulin injectables
TreatmentPreoperative treatmentNote
MetforminTo discontinue on the day of surgeryGastrointestinal discomfort and lactic acidosis should be avoided; Patients with stage 4 severe chronic kidney disease (CKD) [estimated glomerular filtration rate 30 mL·min-1·(1.73 m2)-1] are contraindicated
Sulfonylureas and meglitinidesTo discontinue at the start of preoperative diet (i.e., 2‒4 weeks before surgery)Hypoglycemia and weight gain should be avoided
ThiazolidinedionesTo discontinue on the day of surgeryWeight gain, fluid retention, and edema should all be avoided
ɑ-glucosidase inhibitorsTo discontinue on the day before metabolic surgeryGastrointestinal side effects should be avoided
Dipeptidyl peptidase-4 (DPP-4) inhibitorsTo discontinue on the day of surgeryPatients with heart failure, arthralgia, skin conditions, allergic reactions and acute pancreatitis should use it with caution
Sodium-glucose cotransporter-2 (SGLT2) inhibitors

To discontinue 3 d prior to surgery

(2 weeks prior to surgery for those on a low-calorie ketogenic diet)

Genitourinary tract infections, hypotension, fractures, acute kidney injury, ketoacidosis, and rare cases of Fournier's gangrene should all be taken seriously
Glucagon-like peptide 1 (GLP-1) receptor agonistsTo discontinue on the day of surgeryGastrointestinal side effects should be avoided; Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindicated